Digital Lung Cancer Screening Using Low-Dose CT and AI Assistance in Guangzhou Communities

What this Trial Is About

Researchers are evaluating a digital empowerment model for lung cancer screening aimed at detecting lung cancer earlier and reducing deaths from respiratory diseases. This single-arm cluster randomized trial is conducted in Guangzhou, focusing on community health service centers. The study assesses the effectiveness and cost-effectiveness of low-dose CT LDCT screening combined with AI technology and digital health platforms to improve early lung cancer diagnosis. The intervention includes low-dose CT screenings performed at primary healthcare institutions, supported by an AI-based full-lung model that assists in interpreting CT images. Community health centers use a digital platform called Fei Anxin to manage resident information and coordinate screening efforts. Participants with detected lung nodules are referred to hospitals for further examination. The study expects to enroll about 16,000 participants and collects individual data through questionnaires and digital tools. Participants will undergo lung cancer screening and complete health questionnaires. Screening and diagnostic data are gathered via digital platforms and hospitals. Researchers will measure the proportion of early-stage lung cancer detected within one year after intervention implementation, along with secondary outcomes like follow-up rates, diagnosis rates, false positive rates, and complications related to CT screening and diagnostic tests. The study runs from June 2024 through June 2025 and involves ongoing monitoring and data collection throughout this period.

Early Intervention Strategies for Lung Cancer